Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Lysosomal Storage Disorders: Marking Milestones and Moving Forward

Lysosomal Storage Disorders: Marking Milestones and Moving Forward

January 18th 2012

The mood of the ICHG/ASHG 2011 congress often seemed buoyant as researchers discussed the doors that technology is helping to open.

Dr. Grabowski Explains the Effects of Enzyme Therapy

Dr. Grabowski Explains the Effects of Enzyme Therapy

January 14th 2012

Dr. Gregory Grabowski, from the University Cincinnati, Explains the Effects of Enzyme Therapy

Dr. Mato on the Benefits of the JTCC Retrospective Trial

Dr. Mato on the Benefits of the JTCC Retrospective Trial

December 13th 2011

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

Photos From the 2011 ASH Annual Meeting and Exposition

Photos From the 2011 ASH Annual Meeting and Exposition

December 13th 2011

A collection of photos from the ASH 53rd annual meeting at the San Diego Convention Center in San Diego, CA, from December 10-13, 2011.

Ponatinib Continues March to Potential Front-line Use in CML

Ponatinib Continues March to Potential Front-line Use in CML

December 13th 2011

PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

December 13th 2011

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

December 12th 2011

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

December 12th 2011

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

December 12th 2011

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation

Burden of Morbidity Reported for Long-term Survivors of Hematopoietic Cell Transplantation

December 12th 2011

Bone Marrow Transplant Survivor Study analysis suggests long-term survivors of HCT have high risk of chronic psychological, and physical health conditions

Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

December 11th 2011

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101

Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia

Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia

December 11th 2011

Adding gemtuzumab to chemotherapy improved event-free and OS of newly diagnosed patients with acute myeloid leukemia.

Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)

Peripheral Blood Stem Cell (PBSC) Transplants Increase the Incidence of Graft-Versus-Host Disease (GVHD)

December 11th 2011

Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).

Dr. Kochenderfer Discusses the B-cell Antigen CD19

Dr. Kochenderfer Discusses the B-cell Antigen CD19

December 10th 2011

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

Dr. Feldman Discusses the Difficulties of Rare Lymphomas

Dr. Feldman Discusses the Difficulties of Rare Lymphomas

December 10th 2011

Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas

Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival

Bevacizumab Plus Trastuzumab and Docetaxel Improves Progression-Free Survival

December 9th 2011

A study of bevacizumab in women with HER2-positive metastatic breast cancer demonstrated that combining the drug with standard therapy improves PFS.

Photos From the 2011 San Antonio Breast Cancer Symposium

Photos From the 2011 San Antonio Breast Cancer Symposium

December 9th 2011

A collection of photos from the 34th annual SABCS at the Henry B. Gonzalez Convention Center in San Antonio, TX, from December 6-10, 2011.

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

Breast Cancer Survivors Who Are Mutation Carriers Are at Increased Risk of Cancer in Other Breast

December 9th 2011

Carriers of the BRCA1 or BRCA2 mutation are at greater risk for developing a new primary tumor in the contralateral breast compared with noncarriers.

Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial

Dr. Baselga Discusses the CLEOPATRA Pertuzumab Trial

December 9th 2011

Dr. José Baselga from Massachusetts General Hospital Discusses the CLEOPATRA Pertuzumab Trial

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

Hispanic/Latina Women at Greater Risk of Dying From Breast Cancer Than Non-Hispanic Whites

December 9th 2011

Tumor-related factors that lead to chemotherapy resistance in Hispanic women make them more likely to die from breast cancer than non-Hispanic whites.

Dr. Tripathy on the AVEREL Bevacizumab Trial Results

Dr. Tripathy on the AVEREL Bevacizumab Trial Results

December 9th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

Dual Therapy With Pertuzumab Slows Advanced Breast Cancer

December 9th 2011

The CLEOPATRA trial marks the first time that dual inhibitors have demonstrated value in the treatment of HER2-positive metastatic breast cancer.

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

Dr. Hortobagyi Discusses the BOLERO-2 Everolimus Trial

December 8th 2011

Dr. Gabriel Hortobagyi from the MD Anderson Cancer Center Discusses the BOLERO-2 Trial

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

Exemestane Plus Everolimus New Standard of Care for Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer

December 8th 2011

The BOLERO-2 trial suggests that adding everolimus to hormonal therapy can overcome resistance in patients whose disease progressed.

Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences

Obese Patients With HER2-Positive Breast Cancer Have Worse Outcomes but Trastuzumab Equalizes Weight Differences

December 8th 2011

A large study of HER2+ breast cancer patients shows that obese patients had worse outcomes than normal weight or overweight patients.

Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

Dr. Perez Discusses the CLEOPATRA Pertuzumab Trial

December 8th 2011

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses the CLEOPATRA Pertuzumab Trial

The CLEOPATRA and BOLERO-2 Studies are Stirring Excitement at SABCS

The CLEOPATRA and BOLERO-2 Studies are Stirring Excitement at SABCS

December 7th 2011

The results of 2 studies likely to have a significant impact upon the treatment of women with metastatic breast cancer.

Dr. Smith on the Brachytherapy Breast Cancer Trial

Dr. Smith on the Brachytherapy Breast Cancer Trial

December 7th 2011

Dr. Benjamin Smith from MD Anderson Cancer Center Discusses the Brachytherapy Breast Cancer Trial